This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Kuban DA , Tucker SL , Dong L , Starkschall G , Huang EE , Cheung MR , Lee AK , Pollack A
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer
International Journal of Radiation Oncology Biology Physics. 2008 Jan;70(1) :67-74
AbstractPurpose: To report the long-term results of a randomized radiotherapy dose escalation trial for prostate cancer. Methods and Materials: From 1993 to 1998, a total of 301 patients with stage T1b to T3 prostate cancer were accrued to a randomized external beam dose escalation trial using 70 Gy versus 78 Gy. The median follow-up is now 8.7 years. Kaplan-Meier analysis was used to compute rates of prostate-specific antigen (PSA) failure (nadir + 2), clinical failure, distant metastasis, disease-specific, and overall survival as well as complication rates at 8 years post-treatment. Results: For all patients, freedom from biochemical or clinical failure (FFF) was superior for the 78-Gy arm, 78%, as compared with 59% for the 70-Gy arm (p = 0.004, and an even greater benefit was seen in patients with initial PSA > 10 ng/ml (78% vs. 39%, p = 0.001). The clinical failure rate was significantly reduced in the 78-Gy arm as well (7% vs. 15%, p = 0.014). Twice as many patients either died of prostate cancer or are currently alive with cancer in the 70-Gy arm. Gastrointestinal toxicity of grade 2 or greater occurred twice as often in the high dose patients (26% vs. 13%), although genitourinary toxicity of grade 2 or greater was less (13% vs. 8%) and not statistically significantly different. Dose-volume histogram analysis showed that the complication rate could be significantly decreased by reducing the amount of treated rectum. Conclusions: Modest escalation in radiotherapy dose improved freedom from biochemical and clinical progression with the largest benefit in prostate cancer patients with PSA > 10 ng/ml. (c) 2008 Elsevier Inc.
NotesISI Document Delivery No.: 244LP Times Cited: 0 Cited Reference Count: 25 Cited References: *AM JOINT COMM CAN, 1992, AJCC CANC STAG MAN COX JD, 1995, INT J RADIAT ONCOL, V31, P1341 COX JD, 1997, INT J RADIAT ONCOL, V37, P1035 DAMICO AV, 2003, J UROLOGY 2, V170, S42 DAMICO AV, 2003, J UROLOGY, V170, S46 DAMICO AV, 2004, JAMA-J AM MED ASSOC, V292, P821 HANKS GE, 1988, INT J RADIAT ONCOL, V15, P1299 HANLON AL, 1997, INT J RADIAT ONCOL, V38, P59 HUANG EH, 2002, INT J RADIAT ONCOL, V54, P1314 PAVY JJ, 1995, INT J RADIAT ONCOL, V31, P1043 PEETERS STH, 2006, J CLIN ONCOL, V24, P1990 POLLACK A, 2000, INT J RADIAT ONCOL, V48, P507 POLLACK A, 2000, J CLIN ONCOL, V18, P3904 POLLACK A, 2002, INT J RADIAT ONCOL, V53, P1097 POLLACK A, 2002, INT J RADIAT ONCOL, V54, P677 ROACH M, 2006, INT J RADIAT ONCOL, V65, P965 SCARDINO P, 2005, J NATL COMPR CANC S1, V3, S29 SHIPLEY WU, 1995, INT J RADIAT ONCOL, V32, P3 STOREY MR, 2000, INT J RADIAT ONCOL, V48, P635 TUCKER SL, 2004, INT J RADIAT ONCOL, V59, P353 TUCKER SL, 2004, INT J RADIAT ONCOL, V60, P1589 VANCE W, 2007, INT J RADIAT ONCOL, V67, P828 ZELEFSKY MJ, 2001, J UROLOGY, V166, P876 ZELEFSKY MJ, 2006, J UROLOGY 1, V176, P1415 ZIETMAN AL, 2005, JAMA-J AM MED ASSOC, V294, P1233 Kuban, Deborah A. Tucker, Susan L. Dong, Lei Starkschall, George Huang, Eugene E. Cheung, M. Rex Lee, Andrew K. Pollack, Alan ELSEVIER SCIENCE INC; 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA